[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335552-105":59,"doc-detail-335552-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","contemporary-strategies-for-clinical-chemoprevention-of-localized-prostate-cancer-review-clinical-chemoprevention","Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer - Review - clinical chemoprevention","","Prostate cancer is the most common cancer among U.S. men and remains a leading cause of cancer-related deaths. Most cases in 2016–2020 were diagnosed at a localized stage, yet low-grade disease managed with definitive treatments can lead to overtreatment harms and reduced quality of life without clear cancer-specific mortality benefit. Active surveillance is recommended, but progression prevention through pharmacologic chemoprevention is urgently needed. This review summarizes current agents and approaches for men on active surveillance, identifies gaps, and supports a path toward phase III trials for reducing metastatic progression risk.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/contemporary-strategies-for-clinical-chemoprevention-of-localized-prostate-cancer-review-clinical-chemoprevention/335552/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/contemporary-strategies-for-clinical-chemoprevention-of-localized-prostate-cancer-review-clinical-chemoprevention/335552.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is chemoprevention considered for localized prostate cancer patients on active surveillance?","Question",{"text":112,"@type":113},"Low-grade patients on active surveillance still require novel strategies to prevent progression to metastatic disease through pharmacologic means. The review highlights the urgent need for such chemoprevention approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the role of active surveillance in localized, low-grade prostate cancer?",{"text":117,"@type":113},"Active surveillance is recommended for men with low-grade disease. Although anxiety during active surveillance has been reported, this subgroup is motivated to adopt lifestyle changes to reduce progression risk.",{"name":119,"@type":110,"acceptedAnswer":120},"What limitations exist in current systematic approaches to chemoprevention for men on active surveillance?",{"text":121,"@type":113},"Despite promising agents and approaches studied over the past two decades, the review notes limitations in how agents are systematically examined for chemoprevention in men on active surveillance. It calls for more contemporary and comprehensive strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335552,1790167704,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer  \nCancer Control Volume 31: 1–18  \n© The Author(s) 2024  \nArticle reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748241302863](DOI: 10.1177/10732748241302863)[ ](DOI: 10.1177/10732748241302863)[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nNagi B Kumar, PhD 1 􀀁  \nAbstract  \nProstate cancer (PCa) is the most common cancer among men in the United States and the second leading cause of cancerrelated deaths. Metastatic castration-resistant PCa is still a fatal disease. On the other hand, between 2016 and 2020, about 70% of PCa cases were diagnosed at a localized stage. Evolving data demonstrates that men with low-grade cancers treated with deﬁnitive therapies may now be exposed to morbidities of overtreatment and poor quality of life, with little or no beneﬁt in terms of cancer speciﬁc mortality. Active surveillance (AS) is thus the recommended management strategy for men with lowgrade disease. Although this subgroup of men have reported anxiety during the AS period, they account to be highly motivated to make positive lifestyle changes to further reduce their risk of PCa progression, underscoring the urgent need to identify novel strategies for preventing progression of localized PCa to metastatic disease through pharmacologic means, an approach termed chemoprevention. Although several promising agents and approaches have been examined over the past 2 decades, currently, there are several limitations in the approach used to systematically examine agents for chemoprevention targeting men on AS. The goal of this review is to summarize the current agents and approaches evaluated, targeting men on AS, recognize the gaps, and identify a contemporary and comprehensive path forward. Results of these studies may inform the development of phase III clinical trials and ultimately provide a strategy for clinical chemoprevention in men on AS, for whom, currently, there are no options for reducing the risk of progression to metastatic disease.  \nKeywords  \nprostate cancer, clinical chemoprevention, active surveillance, biomarkers, systematic approach,% Ki-67, serum prostate speciﬁc antigen, gleason score, multiparametric MRI  \nReceived July 11, 2024. Received revised October 24, 2024. Accepted for publication November 8, 2024.  \nIntroduction Prostate Cancer  \nIt is estimated that about 299 010 new cases of prostate cancer (PCa) will be diagnosed in the US in 2024, and 35 250 deaths will occur in men with PCa (ACS 2024) .1 Since the year 2014, the incidence rate of PCa has increased by 3% per year overall and by about 5% per year for advanced-stage PCa. PCa is the most common cancer among men in the US and the second leading cause of cancer-related deaths in the US. Some of the deﬁnitive risk factors associated to PCa includes age, genetic predisposition and race.2 In 2019, 37% of PCa cases were  \n1 Cancer Epidemiology Program, Population Sciences Division, Genitourinary Oncology and Breast Oncology Departments, Department of Oncologic Sciences, Mofﬁtt Cancer Center, University of South Florida College of Medicine, Tampa, FL, USA  \nCorresponding Author:  \nNagi B Kumar, Cancer Epidemiology Program, Population Sciences Division, Genitourinary Oncology and Breast Oncology Departments, Department of Oncologic Sciences, Mofﬁtt Cancer Center, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA.  \nEmail: nagi.kumar@mofﬁ[tt.org](tt.org)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE ","cbCaibVzlHeH5nos","https://ap.wps.com/l/cbCaibVzlHeH5nos","pdf",757701,18,"English","# Abstract\n# Introduction Prostate Cancer\n## Epidemiology and risk factors\n## Treatment standards and emergence of active surveillance\n## Biomarkers and diagnosis at localized stages","[{\"question\":\"Why is chemoprevention considered for localized prostate cancer patients on active surveillance?\",\"answer\":\"Low-grade patients on active surveillance still require novel strategies to prevent progression to metastatic disease through pharmacologic means. The review highlights the urgent need for such chemoprevention approaches.\"},{\"question\":\"What is the role of active surveillance in localized, low-grade prostate cancer?\",\"answer\":\"Active surveillance is recommended for men with low-grade disease. Although anxiety during active surveillance has been reported, this subgroup is motivated to adopt lifestyle changes to reduce progression risk.\"},{\"question\":\"What limitations exist in current systematic approaches to chemoprevention for men on active surveillance?\",\"answer\":\"Despite promising agents and approaches studied over the past two decades, the review notes limitations in how agents are systematically examined for chemoprevention in men on active surveillance. It calls for more contemporary and comprehensive strategies.\"}]","Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer - Review - clinical chemoprevention | PDF",1790011416,45]